A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The British journal of psychiatry : the journal of mental science

• Publication date

  2014-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1192/bjp.bp.113.138578PMID 24986384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

  2012cited by this paper
• Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia: A 12-Week, Double-Blind, Placebo-Controlled Trial

  2012cited by this paper
• The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

  2012cited by this paper
• Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

  2012cited by this paper
• Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study

  2011cited by this paper
• Dopaminergic synapses in the caudate of subjects with schizophrenia: Relationship to treatment response

  2009cited by this paper
• Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging.

  2008cited by this paper
• Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia

  2003cited by this paper
• Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

  2000cited by this paper
• A biomodal distribution of plasma HVA/MHPG in the psychoses.

  1997cited by this paper
• [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders].

  1993cited by this paper

• [Biological aspects of drug resistance in schizophrenia].

  2026cites this paper
• Two-month antipsychotic exposure induces domain-specific eye movement alterations in clinical high-risk individuals.

  2025cites this paper
• The hypothesis of biologically based subtypes of schizophrenia: a 10‐year update

  2025cites this paper
• The sense and nonsense of antipsychotic combinations: A model for dopamine D2/3 receptor occupancy

  2025cites this paper
• Pharmacogenetic Biomarkers of Clozapine-Induced Sialorrhoea: A Systematic Review

  2025cites this paper
• The relationship between neuromelanin, glutamate, and GABA in first-episode psychosis: A multimodal magnetic resonance imaging study.

  2025cites this paper
• Neural bases of referential thinking in schizophrenia spectrum disorders and high-risk mental states: A systematic review

  2025cites this paper
• Neuroinflamation Treatment Options in Resistant Schizophrenia—State of the Art

  2025cites this paper
• Putative Mechanisms of Electroconvulsive Therapy in Treatment-Resistant Schizophrenia Examined Using Magnetic Resonance Imaging

  2025cites this paper
• In vivo assessment of GABAergic inhibition and glutamate facilitation in treatment-resistant schizophrenia: a TMS study integrating clinical, cognitive, and neurophysiological evaluations

  2025cites this paper
• Neuroanatomical comparison of treatment-resistant and treatment-responsive schizophrenia patients using the cloud-based brain magnetic resonance image segmentation and parcellation system: An MRIcloud study.

  2024cites this paper
• Structural MRI of the Brain in Treatment-Resistant Schizophrenia

  2024cites this paper
• Considering people at clinical high risk for psychosis with normodopaminergia: Clinical case of progression to treatment-resistant schizophrenia in three years.

  2024cites this paper
• Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.

  2024cites this paper
• Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia

  2024cites this paper
• Psychotropic Taxonomies: Constructing a Therapeutic Framework for Psychiatry

  2024cites this paper
• Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study.

  2024cites this paper
• Neurostructural subgroup in 4291 individuals with schizophrenia identified using the subtype and stage inference algorithm

  2024cites this paper
• Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation

  2024cites this paper
• Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice.

  2024cites this paper
• Distinctive Patterns of 5-Methylcytosine and 5-Hydroxymethylcytosine in Schizophrenia

  2024cites this paper
• Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

  2024cites this paper
• Unique Challenges in Biomarkers for Psychotic Disorders

  2024cites this paper
• Identification of novel functional brain proteins for treatment-resistant schizophrenia: Based on a proteome-wide association study

  2023cites this paper
• Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography

  2023cites this paper
• The phenomenon of therapeutic resistance in the treatment of schizophrenia: the possibilities of modern diagnostics and methods of anti-resistant effects

  2023cites this paper
• Mygalin, an Acanthoscurria gomesiana spider-derived synthetic, modulates haloperidol-induced cataleptic state in mice.

  2023cites this paper
• Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia

  2023cites this paper
• Striatal dopamine synthesis capacity and neuromelanin in the substantia nigra: A multimodal imaging study in schizophrenia and healthy controls

  2023cites this paper
• Clinical response to treatment with a partial dopamine agonist is related to changes in reward processing.

  2023cites this paper
• Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response

  2023cites this paper
• Attenuation of Stimulated Accumbal Dopamine Release by NMDA Is Mediated through Metabotropic Glutamate Receptors

  2023cites this paper
• Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review

  2023cites this paper
• Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal

  2023cites this paper
• The substantia nigra in the pathology of schizophrenia: A review on post-mortem and molecular imaging findings.

  2023cites this paper
• Markers of muscarinic deficit for individualized treatment in schizophrenia

  2023cites this paper
• Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance.

  2022cites this paper
• Replication of the abnormal niacin response in first episode psychosis measured using laser Doppler flowmeter

  2022cites this paper
• The pharmacological treatment of schizophrenia: How far have we come?

  2022cites this paper
• Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol

  2022cites this paper
• The relationship between glutamate, dopamine, and cortical gray matter: A simultaneous PET-MR study

  2022cites this paper
• Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study.

  2022cites this paper
• A New Treatment Paradigm

  2022cites this paper
• The Interrelation between Interleukin-2 and Schizophrenia

  2022cites this paper
• The Construct of Medical and Non-Medical Marijuana—Critical Review

  2022cites this paper
• Treatment-resistant schizophrenia: How far have we traveled?

  2022cites this paper
• The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients

  2022cites this paper
• Circuit-Based Approaches to Understanding Corticostriatothalamic Dysfunction Across the Psychosis Continuum.

  2022cites this paper
• Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics

  2022cites this paper
• The Relationship Between Frontostriatal Connectivity and Striatal Dopamine Function in Schizophrenia: An 18 F-DOPA PET and Diffusion Tensor Imaging Study in Treatment Responsive and Resistant Patients

  2022cites this paper
• The Relationship Between Frontostriatal Connectivity and Striatal Dopamine Function in Schizophrenia: An 18 F-DOPA PET and Diffusion Tensor Imaging Study in Treatment Responsive and Resistant Patients

  2022cites this paper
• Glycolytic and Krebs cycle enzymes activity in rat prefrontal cortex, hippocampus, and striatum after single and repeated NMDA inhibition by MK-801.

  2022cites this paper
• King’s Research Portal

  2022cites this paper
• The Relationship Between Frontostriatal Connectivity and Striatal Dopamine Function in Schizophrenia: An 18F-DOPA PET and Diffusion Tensor Imaging Study in Treatment Responsive and Resistant Patients

  2022cites this paper
• The mGlu7 receptor in schizophrenia - An update and future perspectives.

  2022cites this paper
• A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

  2022cites this paper
• Striatal dopamine synthesis capacity and its association with negative symptoms upon resolution of positive symptoms in first-episode schizophrenia and delusional disorder

  2022cites this paper
• The utility of PET imaging in the diagnosis and management of psychosis: a brief review

  2021cites this paper
• Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia.

  2021cites this paper
• Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders

  2021cites this paper
• Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study

  2021cites this paper
• Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment

  2021cites this paper
• Striatal dopamine D2/3 receptors in medication-naïve schizophrenia: an [123I] IBZM SPECT study

  2021cites this paper
• Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis

  2021cites this paper
• Reduced resting state functional connectivity in the hippocampus-midbrain-striatum network of schizophrenia patients.

  2021cites this paper
• Modulation of stimulated dopamine release in rat nucleus accumbens shell by GABA in vitro: Effect of sub‐chronic phencyclidine pretreatment

  2021cites this paper
• The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study.

  2021cites this paper
• Dopaminergic Activity in Antipsychotic-naïve Patients Assessed with PET Before and After Partial Dopamine D2-receptor Agonist Treatment: Association with Psychotic Symptoms and Treatment Response

  2021cites this paper
• We are not ready to abandon the current schizophrenia construct, but should be prepared to do so.

  2021cites this paper
• Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients.

  2021cites this paper
• Assessment of treatment resistance criteria in non-invasive brain stimulation studies of schizophrenia.

  2021cites this paper
• Resting-state functional connectivity predictors of treatment response in schizophrenia - A systematic review and meta-analysis.

  2021cites this paper
• Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response.

  2021cites this paper
• From hallucinations to synaesthesia: a circular inference account of unimodal and multimodal erroneous percepts in clinical and drug-induced psychosis.

  2021cites this paper
• Treatment resistance in psychiatry: state of the art and new directions

  2021cites this paper
• S0033291720005413jra 1..9

  2021cites this paper
• Striatal functional connectivity in psychosis relapse: A hypothesis generating study.

  2021cites this paper
• Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)

  2020cites this paper
• Striatal functional connectivity in psychosis relapse: A comparison between antipsychotic adherent and non-adherent patients at the time of relapse

  2020cites this paper
• Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance.

  2020cites this paper
• Amphetamine-induced striatal dopamine release in schizotypal personality disorder

  2020cites this paper
• Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)

  2020cites this paper
• Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques

  2020cites this paper
• Clinical and cognitive correlates of childhood attention-deficit/hyperactivity disorder in first-episode psychosis: A controlled study.

  2020cites this paper
• Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response

  2020cites this paper
• Distinguishing Schizophrenia Subtypes: Can Dopamine Imaging Improve the Signal-to-Noise Ratio?

  2020cites this paper
• The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research

  2020influential citation
• Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case–control study

  2020cites this paper
• Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment

  2020cites this paper
• Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

  2020cites this paper
• Dopamine and Response to Antipsychotic Medication

  2020cites this paper
• Paranoid Personality Disorder

  2020cites this paper
• Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis.

  2020cites this paper
• A neuroimaging biomarker for striatal dysfunction in schizophrenia

  2020cites this paper
• Bridging the associations between dopamine, brain volumetric variation and IQ in drug-naïve schizophrenia.

  2020cites this paper
• Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model

  2020cites this paper
• Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery

  2020cites this paper
• Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission

  2020cites this paper
• Striatal dopamine, functional connectivity, and salience processing in health and disease

  2019cites this paper
• Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

  2019cites this paper